6U7O image
Deposition Date 2019-09-03
Release Date 2019-10-09
Last Version Date 2023-10-11
Entry Detail
PDB ID:
6U7O
Keywords:
Title:
HIV-1 wild type protease with GRL-00819A, with phenyl-boronic-acid as P2'-ligand and with a 6-5-5-ring fused crown-like tetrahydropyranofuran as the P2-ligand
Biological Source:
Source Organism:
Method Details:
Experimental Method:
Resolution:
1.33 Å
R-Value Free:
0.17
R-Value Work:
0.13
R-Value Observed:
0.13
Space Group:
P 21 21 2
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Protease
Gene (Uniprot):pol
Chain IDs:A, B
Chain Length:99
Number of Molecules:2
Biological Source:Human immunodeficiency virus 1
Primary Citation
Potent HIV-1 Protease Inhibitors Containing Carboxylic and Boronic Acids: Effect on Enzyme Inhibition and Antiviral Activity and Protein-Ligand X-ray Structural Studies.
Chemmedchem 14 1863 1872 (2019)
PMID: 31549492 DOI: 10.1002/cmdc.201900508

Abstact

We report the synthesis and biological evaluation of phenylcarboxylic acid and phenylboronic acid containing HIV-1 protease inhibitors and their functional effect on enzyme inhibition and antiviral activity in MT-2 cell lines. Inhibitors bearing bis-THF ligand as P2 ligand and phenylcarboxylic acids and carboxamide as the P2' ligands, showed very potent HIV-1 protease inhibitory activity. However, carboxylic acid containing inhibitors showed very poor antiviral activity relative to carboxamide-derived inhibitors which showed good antiviral IC50 value. Boronic acid derived inhibitor with bis-THF as the P2 ligand showed very potent enzyme inhibitory activity, but it showed lower antiviral activity than darunavir in the same assay. Boronic acid containing inhibitor with a P2-Crn-THF ligand also showed potent enzyme Ki but significantly decreased antiviral activity. We have evaluated antiviral activity against a panel of highly drug-resistant HIV-1 variants. One of the inhibitors maintained good antiviral activity against HIVDRVRP20 and HIVDRVRP30 viruses. We have determined high resolution X-ray structures of two synthetic inhibitors bound to HIV-1 protease and obtained molecular insight into the ligand-binding site interactions.

Legend

Protein

Chemical

Disease

Primary Citation of related structures